Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: infigratinib
Trade Name: Truseltiq
Date Designated: 09/11/2019
Orphan Designation: Treatment of cholangiocarcinoma
Orphan Designation Status: Designated/Approved
QED Therapeutics, Inc.
8000 Marina Boulevard
Suite 400
Brisbane, California 94005
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: infigratinib
Trade Name: Truseltiq
Marketing Approval Date: 05/28/2021
Approved Labeled Indication: Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Exclusivity End Date: 05/28/2028 
Exclusivity Protected Indication* :  Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-